Compare Mercadolibre Inc (MELI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Neurocrine Biosciences Inc — how do they compare? Mercadolibre Inc trades at $1,930 (market cap $98.35B), while Neurocrine Biosciences Inc trades at $152.18 (market cap $16.46B). The key difference: Mercadolibre Inc is far larger — about 6× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| MELI | NBIX | |
|---|---|---|
Market Cap | $98.35B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $185.50 |
52-Week Low | $1.55K | $123.10 |
Enterprise Value | $106.00B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
